WESTCORT (hydrocortisone valerate) by PharmaIN is clinical pharmacology like other topical corticosteroids, hydrocortisone valerate has anti-inflammatory, antipruritic and vasoconstrictive properties. First approved in 1983.
Drug data last refreshed 22h ago · AI intelligence enriched 2w ago
WESTCORT (hydrocortisone valerate) is a topical corticosteroid ointment formulation with medium potency used to treat inflammatory skin conditions. It works by inhibiting phospholipase A2 and reducing the production of inflammatory mediators such as prostaglandins and leukotrienes. The drug exhibits anti-inflammatory, antipruritic, and vasoconstrictive properties.
As a legacy topical corticosteroid approaching loss of exclusivity with moderate competitive pressure, the brand team is likely consolidating and shifting toward generic optimization or niche positioning.
CLINICAL PHARMACOLOGY Like other topical corticosteroids, hydrocortisone valerate has anti-inflammatory, antipruritic and vasoconstrictive properties. The mechanism of the anti-inflammatory activity of the topical steroids, in general, is unclear. However, corticosteroids are thought to act by the…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on WESTCORT at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on WESTCORT offers limited career growth opportunity as the product approaches loss of exclusivity with minimal linked job postings. Career trajectory on this product is primarily focused on managing decline, optimizing market share retention, and transitioning to generic or authorized generic strategies.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo